Annals of Hematology
Papers 9616
1 page of 962 pages (9,616 results)
#1Srdan Verstovsek (University of Texas at Austin)H-Index: 112
#2Shreekant Parasuraman (Incyte)H-Index: 7
Last. Claire N. Harrison (Guy's and St Thomas' NHS Foundation Trust)H-Index: 72
view all 7 authors...
The Janus kinase inhibitor ruxolitinib is approved for the treatment of myelofibrosis (MF) and improved overall survival (OS) versus control therapy in the phase 3 COMFORT trials. The aim of this retrospective analysis was to examine the real-world impact of ruxolitinib on OS in patients with MF. The US Medicare Fee-for-Service claims database (parts A/B/D) was used to identify patients with ≥ 1 inpatient or ≥ 2 outpatient claims with an MF diagnosis (January 2010-December 2017). Eligible patien...
#2Libo Sun (Geron Corporation)H-Index: 4
Last. Aleksandra Rizo (Geron Corporation)H-Index: 7
view all 13 authors...
In the MYF2001 trial, treatment of Janus kinase (JAK) inhibitor-relapsed/refractory intermediate-2 or high-risk myelofibrosis (MF) with imetelstat 9.4 mg/kg every 3 weeks demonstrated encouraging median overall survival of 29.9 months. To provide historical context, external real-world data (RWD) were collected from a study of 96 patients who had discontinued ruxolitinib and were subsequently treated with best available therapy (BAT) at Moffitt Cancer Center. A closely matched cohort was identif...
#1Ka-Won Kang (KU: Korea University)H-Index: 2
#2Hyemi Moon (KU: Korea University)H-Index: 2
Last. Byung Soo Kim (KU: Korea University)H-Index: 23
view all 12 authors...
#1Kelsey Uminski (U of O: University of Ottawa)
#2Roy Khalife (U of O: University of Ottawa)H-Index: 1
Last. Alan Tinmouth (U of O: University of Ottawa)H-Index: 39
view all 6 authors...
#1Inbar Cohen (Tel Aviv Sourasky Medical Center)
#2Hadar Goldvaser (Shaare Zedek Medical Center)H-Index: 9
Last. Daniel Shepshelovich (TAU: Tel Aviv University)H-Index: 11
view all 7 authors...
Several targeted therapies have been approved in recent years for second-line treatment of immune thrombocytopenic purpura (ITP), providing an alternative to rituximab and splenectomy. The extent to which these drugs reduce bleeding risk has not been well defined. Targeted therapies recently approved for the treatment of ITP in adults were identified through a search of recently published professional guidelines. Randomized controlled trials (RCTs) supporting regulatory approval were identified ...
#1Nashwa El-Khazragy (Ain Shams University)H-Index: 7
#2Safa Matbouly (Ain Shams University)H-Index: 3
Last. Soha Abuelela (Ain Shams University)
view all 8 authors...
#1Alexandra-Cristina Paunescu (Institut Gustave Roussy)
#2Christiane CopieH-Index: 1
Last. Nicolas MounierH-Index: 54
view all 13 authors...
Health-related quality of life (HRQoL) is a multidimensional concept including physical, emotional, social, and cognitive functions, disease symptoms, and side effects of treatment. Differences in HRQoL due to gender, existence of comorbidities, and number of chemotherapy cycles are little explored in diffuse large B-cell lymphoma (DLBCL) survivors. Our objective was to investigate whether differences in HRQoL in function of these factors exist 1 year after the diagnosis of DLBCL. One hundred an...
#1Damien Luque Paz (University of Angers)H-Index: 9
#2Laurane Cottin (University of Angers)H-Index: 5
Last. Barbara BurroniH-Index: 9
view all 14 authors...
#1Xiaojun Wang (Peking Union Medical College)
#2Yi Miao (Nanjing Medical University)H-Index: 33
Last. Xiaoli Feng (Peking Union Medical College)H-Index: 19
view all 6 authors...
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is a type of low-grade malignant B-cell lymphoma. The aim of this study was to investigate the clinicopathological characteristics of thymic MALT lymphoma. We analyzed the clinical, morphological, immunophenotypical, cytogenetic, and molecular characteristics of 11 cases of thymic MALT lymphoma. The relevant literature was also reviewed. The median age of the 11 patients was 50 (range: 33-60). There was...
#1Eugene Brailovski (U of T: University of Toronto)H-Index: 1
#2Hubert Tsui (Sunnybrook Health Sciences Centre)H-Index: 1
Last. Rena Buckstein (Sunnybrook Health Sciences Centre)H-Index: 36
view all 6 authors...
Top fields of study
Bone marrow
Diabetes mellitus